168 related articles for article (PubMed ID: 32618536)
1. Assessment of technical errors and validation processes in economic models submitted by the company for NICE technology appraisals.
Radeva D; Hopkin G; Mossialos E; Borrill J; Osipenko L; Naci H
Int J Technol Assess Health Care; 2020 Jul; ():1-6. PubMed ID: 32618536
[TBL] [Abstract][Full Text] [Related]
2. What Is the Evidence from Past National Institute of Health and Care Excellence Single-Technology Appraisals Regarding Company Submissions with Base-Case Incremental Cost-Effectiveness Ratios of Less Than £10,000/QALY?
Carroll C; Houten R; Boland A; Kaltenthaler E; Dickson R
Value Health; 2018 Mar; 21(3):341-350. PubMed ID: 29566842
[TBL] [Abstract][Full Text] [Related]
3. The use of exploratory analyses within the National Institute for Health and Care Excellence single technology appraisal process: an evaluation and qualitative analysis.
Kaltenthaler E; Carroll C; Hill-McManus D; Scope A; Holmes M; Rice S; Rose M; Tappenden P; Woolacott N
Health Technol Assess; 2016 Apr; 20(26):1-48. PubMed ID: 27049841
[TBL] [Abstract][Full Text] [Related]
4. Real-world evidence use in assessments of cancer drugs by NICE.
Bullement A; Podkonjak T; Robinson MJ; Benson E; Selby R; Hatswell AJ; Shields GE
Int J Technol Assess Health Care; 2020 Jul; ():1-7. PubMed ID: 32646531
[TBL] [Abstract][Full Text] [Related]
5. Assessment of quality of data submitted for NICE technology appraisals over two decades.
Osipenko L; Ul-Hasan SA; Winberg D; Prudyus K; Kousta M; Rizoglou A; Rustignoli I; van der Maas L
BMJ Open; 2024 Feb; 14(2):e074341. PubMed ID: 38351112
[TBL] [Abstract][Full Text] [Related]
6. How Do Pharmaceutical Companies Model Survival of Cancer Patients? A Review of NICE Single Technology Appraisals in 2017.
Gallacher D; Auguste P; Connock M
Int J Technol Assess Health Care; 2019 Jan; 35(2):160-167. PubMed ID: 31017564
[TBL] [Abstract][Full Text] [Related]
7. Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Mistry H; Nduka C; Connock M; Colquitt J; Mantopoulos T; Loveman E; Walewska R; Mason J
Pharmacoeconomics; 2018 Apr; 36(4):399-406. PubMed ID: 29222670
[TBL] [Abstract][Full Text] [Related]
8. Does Methodological Guidance Produce Consistency? A Review of Methodological Consistency in Breast Cancer Utility Value Measurement in NICE Single Technology Appraisals.
Rose M; Rice S; Craig D
Pharmacoecon Open; 2018 Jun; 2(2):97-107. PubMed ID: 29623616
[TBL] [Abstract][Full Text] [Related]
9. The Type and Impact of Evidence Review Group Exploratory Analyses in the NICE Single Technology Appraisal Process.
Carroll C; Kaltenthaler E; Hill-McManus D; Scope A; Holmes M; Rice S; Rose M; Tappenden P; Woolacott N
Value Health; 2017 Jun; 20(6):785-791. PubMed ID: 28577696
[TBL] [Abstract][Full Text] [Related]
10. Evidence Review Group approaches to the critical appraisal of manufacturer submissions for the NICE STA process: a mapping study and thematic analysis.
Kaltenthaler E; Boland A; Carroll C; Dickson R; Fitzgerald P; Papaioannou D
Health Technol Assess; 2011 May; 15(22):1-82, iii-iv. PubMed ID: 21561569
[TBL] [Abstract][Full Text] [Related]
11. A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the National Institute for Health and Care Excellence: how did the initial best estimate compare to trial data subsequently made available?
Bullement A; Meng Y; Cooper M; Lee D; Harding TL; O'Regan C; Aguiar-Ibanez R
J Med Econ; 2019 Mar; 22(3):205-214. PubMed ID: 30422080
[TBL] [Abstract][Full Text] [Related]
12. A Review of Survival Analysis Methods Used in NICE Technology Appraisals of Cancer Treatments: Consistency, Limitations, and Areas for Improvement.
Bell Gorrod H; Kearns B; Stevens J; Thokala P; Labeit A; Latimer N; Tyas D; Sowdani A
Med Decis Making; 2019 Nov; 39(8):899-909. PubMed ID: 31707911
[No Abstract] [Full Text] [Related]
13. Appraisals by Health Technology Assessment Agencies of Economic Evaluations Submitted as Part of Reimbursement Dossiers for Oncology Treatments: Evidence from Canada, the UK, and Australia.
Ball G; Levine MAH; Thabane L; Tarride JE
Curr Oncol; 2022 Oct; 29(10):7624-7636. PubMed ID: 36290879
[TBL] [Abstract][Full Text] [Related]
14. A Review of Issues Affecting the Efficiency of Decision Making in the NICE Single Technology Appraisal Process.
Walton MJ; O'Connor J; Carroll C; Claxton L; Hodgson R
Pharmacoecon Open; 2019 Sep; 3(3):403-410. PubMed ID: 30617953
[TBL] [Abstract][Full Text] [Related]
15. Utility values in National Institute for Health and Clinical Excellence (NICE) Technology Appraisals.
Tosh JC; Longworth LJ; George E
Value Health; 2011 Jan; 14(1):102-9. PubMed ID: 21211492
[TBL] [Abstract][Full Text] [Related]
16. Cross-sectional analysis of use of real-world data in single technology appraisals of oncological medicine by the National Institute for Health and Care Excellence in 2011-2021.
Kang J; Cairns J
BMJ Open; 2024 Mar; 14(3):e077297. PubMed ID: 38485485
[TBL] [Abstract][Full Text] [Related]
17. Single technology appraisals by NICE: are they delivering faster guidance to the NHS?
Barham L
Pharmacoeconomics; 2008; 26(12):1037-43. PubMed ID: 19014204
[TBL] [Abstract][Full Text] [Related]
18. A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.
Jäkel A; Plested M; Dharamshi K; Modha R; Bridge S; Johns A
Appl Health Econ Health Policy; 2013 Feb; 11(1):27-43. PubMed ID: 23329379
[TBL] [Abstract][Full Text] [Related]
19. Issues Related to the Frequency of Exploratory Analyses by Evidence Review Groups in the NICE Single Technology Appraisal Process.
Kaltenthaler E; Carroll C; Hill-McManus D; Scope A; Holmes M; Rice S; Rose M; Tappenden P; Woolacott N
Pharmacoecon Open; 2017 Jun; 1(2):99-108. PubMed ID: 29442332
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
